Immune regulation and control of regulatory T cells by OX40 and 4-1BB - PubMed (original) (raw)
Review
Immune regulation and control of regulatory T cells by OX40 and 4-1BB
Takanori So et al. Cytokine Growth Factor Rev. 2008 Jun-Aug.
Abstract
The TNFR family members OX40 (CD134) and 4-1BB (CD137) have been found to play major roles as costimulatory receptors for both CD4 and CD8 T cells. In particular, in many situations, they can control proliferation, survival, and cytokine production, and hence are thought to dictate accumulation of protective T cells during anti-viral and anti-tumor responses and pathogenic T cells during autoimmune reactions. As opposed to simply controlling the activity of naïve, effector, and memory T cells, recent data have suggested that both molecules are also instrumental in controlling the generation and activity of so-called regulatory or suppressor T cells (Treg), perhaps in both positive and negative manners. Part of the action on Treg might function to further promote protective or pathogenic T cells, but alternate activities of OX40 and 4-1BB on Treg are also being described that suggest that there might be control by these molecules at multiple levels that will alter the biological outcome when these receptors are ligated. This review specifically focuses on recent studies of regulatory T cells, and regulatory or suppressive activity, that are modulated by OX40 or 4-1BB.
Figures
Figure 1
Subsets of Treg Control Effector CD4 and CD8 cells. Regulatory T cells can exist as either natural Treg (nTreg) that derive in the thymus and express CD4 and Foxp3, or as inducible or adaptive Treg (iTreg) that derive in the periphery from naïve CD4+ or CD8+ T cells in response to factors such as TGF-β or IL-10. The latter can be Foxp3+ or Foxp3- and may make suppressive cytokines such as TGF-β or IL-10. Emerging evidence suggests that either nTreg or iTreg limit inflammation and autoimmunity by directly or indirectly suppressing the activity of effector CD4 or CD8 T cells (Th1/Th2/Th17/CTL). Both effector T cells and Treg express surface receptors, either constitutively or inducibly, that can modulate their activity, such as CD28 and CD25, and TNFR superfamily molecules such as OX40, 4-1BB, and GITR.
Figure 2
OX40 and 4-1BB May Exert Multiple Activities in Controlling Treg Generation or Function. OX40 and 4-1BB potentially can modulate Treg activity at several stages. OX40 inhibits development of Foxp3+ iTreg and Foxp3- IL-10-producing Tr1 Treg that are generated from naïve CD4 T cells. Whether 4-1BB possesses this activity is not known. Both OX40 and 4-1BB can promote proliferation and/or survival of already existing Foxp3+ iTreg and nTreg, and also can inhibit the regulatory/suppressive activity of these cells. Whether promotion of proliferation/survival are directly linked to loss of suppressive capacity is not known. OX40 can also downregulate IL-10 secretion, likely linked to loss of suppressive activity by Tr1 Treg. 4-1BB on the other hand can promote the development or expansion of CD8+ Treg that are Foxp3- and may in some cases express CD11c. It is not known if OX40 has the latter capacity.
Similar articles
- Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
Lee SW, Park Y, Song A, Cheroutre H, Kwon BS, Croft M. Lee SW, et al. J Immunol. 2006 Oct 1;177(7):4464-72. doi: 10.4049/jimmunol.177.7.4464. J Immunol. 2006. PMID: 16982882 - During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, Ishii N, Borst J. Hendriks J, et al. J Immunol. 2005 Aug 1;175(3):1665-76. doi: 10.4049/jimmunol.175.3.1665. J Immunol. 2005. PMID: 16034107 - 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
Dawicki W, Bertram EM, Sharpe AH, Watts TH. Dawicki W, et al. J Immunol. 2004 Nov 15;173(10):5944-51. doi: 10.4049/jimmunol.173.10.5944. J Immunol. 2004. PMID: 15528328 - Costimulation of T cells by OX40, 4-1BB, and CD27.
Croft M. Croft M. Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):265-73. doi: 10.1016/s1359-6101(03)00025-x. Cytokine Growth Factor Rev. 2003. PMID: 12787564 Review. - The role of OX40-mediated co-stimulation in T-cell activation and survival.
Redmond WL, Ruby CE, Weinberg AD. Redmond WL, et al. Crit Rev Immunol. 2009;29(3):187-201. doi: 10.1615/critrevimmunol.v29.i3.10. Crit Rev Immunol. 2009. PMID: 19538134 Free PMC article. Review.
Cited by
- Bone Morphogenetic Proteins Shape Treg Cells.
Kraj P. Kraj P. Front Immunol. 2022 Mar 28;13:865546. doi: 10.3389/fimmu.2022.865546. eCollection 2022. Front Immunol. 2022. PMID: 35418975 Free PMC article. Review. - SHIP limits immunoregulatory capacity in the T-cell compartment.
Collazo MM, Wood D, Paraiso KH, Lund E, Engelman RW, Le CT, Stauch D, Kotsch K, Kerr WG. Collazo MM, et al. Blood. 2009 Mar 26;113(13):2934-44. doi: 10.1182/blood-2008-09-181164. Epub 2009 Jan 9. Blood. 2009. PMID: 19136659 Free PMC article. - Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus.
Abe J, Ueha S, Suzuki J, Tokano Y, Matsushima K, Ishikawa S. Abe J, et al. Am J Pathol. 2008 Dec;173(6):1682-92. doi: 10.2353/ajpath.2008.080314. Epub 2008 Nov 13. Am J Pathol. 2008. PMID: 19008373 Free PMC article. - A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P, Bhattacharya P, Prabhakar BS. Kumar P, et al. J Autoimmun. 2018 Dec;95:77-99. doi: 10.1016/j.jaut.2018.08.007. Epub 2018 Aug 31. J Autoimmun. 2018. PMID: 30174217 Free PMC article. Review. - Proteomics reveals unique identities of human TGF-β-induced and thymus-derived CD4+ regulatory T cells.
Mensink M, Schrama E, Cuadrado E, Amsen D, de Kivit S, Borst J. Mensink M, et al. Sci Rep. 2022 Nov 24;12(1):20268. doi: 10.1038/s41598-022-23515-z. Sci Rep. 2022. PMID: 36434024 Free PMC article.
References
- Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003;14:265–73. - PubMed
- Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature reviews. 2003;3:609–20. - PubMed
- Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68. - PubMed
- Vinay DS, Kwon BS. Immunotherapy targeting 4-1BB and its ligand. International journal of hematology. 2006;83:23–8. - PubMed
- Vinay DS, Cha K, Kwon BS. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med. 2006;84:726–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA091837-04/CA/NCI NIH HHS/United States
- U19 AI070535-010003/AI/NIAID NIH HHS/United States
- U19 AI070535/AI/NIAID NIH HHS/United States
- U19 AI070535-020003/AI/NIAID NIH HHS/United States
- R01 CA091837-03/CA/NCI NIH HHS/United States
- AI070535/AI/NIAID NIH HHS/United States
- R01 AI049453/AI/NIAID NIH HHS/United States
- R01 AI042944-07/AI/NIAID NIH HHS/United States
- R01 AI042944/AI/NIAID NIH HHS/United States
- R01 CA091837-05/CA/NCI NIH HHS/United States
- AI49453/AI/NIAID NIH HHS/United States
- R01 AI042944-08/AI/NIAID NIH HHS/United States
- R01 CA091837/CA/NCI NIH HHS/United States
- CA91837/CA/NCI NIH HHS/United States
- R01 CA091837-01A1/CA/NCI NIH HHS/United States
- R01 AI042944-06/AI/NIAID NIH HHS/United States
- AI42944/AI/NIAID NIH HHS/United States
- R01 CA091837-02/CA/NCI NIH HHS/United States
- R01 AI042944-09/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials